Completed OBSERVATIONAL NCT04027543

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

Clinical Evidence for Association of Neoadjuvant Chemotherapy or Chemoradiotherapy With Efficacy and Safety in Patients With Resectable Esophageal Carcinoma (NewEC Study)

Sponsor: Guangdong Provincial People's Hospital

Conditions Chemotherapy Effect Effect of Drugs Oesophageal Carcinoma Radiotherapy Side Effect Safety Issues

Interventions Neoadjuvant chemoradiotherapy Neoadjuvant chemotherapy Oesophagectomy

Updated 5 times since 2019 Last updated: May 27, 2020 Started: Nov 14, 2018 Primary completion: Dec 1, 2019 Completion: Dec 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Chemotherapy Effect and Effect of Drugs, this trial is completed. The trial is conducted by Guangdong Provincial People's Hospital and has accumulated 5 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2020 — Jan 2021 [monthly]

Completed
Aug 2019 — Jun 2020 [monthly]

Completed

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Provincial People's Hospital
Massachusetts General Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Guangzhou, China